Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Ospedale Papa Giovanni XXIII, Bergamo, Italy.
R
R
Labianca
B
B
Nordlinger
G D
GD
Beretta
S
S
Mosconi
M
M
Mandalà
A
A
Cervantes
D
D
Arnold
D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000069287:Capecitabine; D002272:Carcinoembryonic Antigen / Q000097:blood; D017024:Chemotherapy, Adjuvant; D002872:Chromosome Deletion; D025063:Chromosome Disorders / Q000235:genetics; D002887:Chromosomes, Human, Pair 18 / Q000235:genetics; D003110:Colonic Neoplasms / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy*; D003113:Colonoscopy; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D055088:Early Detection of Cancer; D005060:Europe / Q000453:epidemiology; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D007413:Intestinal Mucosa / Q000473:pathology; D002955:Leucovorin / Q000627:therapeutic use; D008207:Lymphatic Metastasis; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000628:therapy; D009367:Neoplasm Staging; D009780:Occult Blood; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D010071:Oxaloacetates; D012306:Risk; D018570:Risk Assessment; D012307:Risk Factors; D012812:Sigmoidoscopy; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D002272:Carcinoembryonic Antigen; D009944:Organoplatinum Compounds; D010071:Oxaloacetates; D003841:Deoxycytidine; D000069287:Capecitabine; D002955:Leucovorin; D005472:Fluorouracil